1 0
Cart
    Inquiry
    Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein

    Anti-F11 Recombinant Antibody Products

    Loading...

    Anti-F11 Products

    + Filter
    Loading...
    View More Products

    Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

    More Infomation

    Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    For Research Use Only. Not For Clinical Use.


    Creative Biolabs is a leader in thrombosis research, providing unparalleled anti-F11 recombinant antibodies. Coagulation Factor XI (F11) is a novel target for new anticoagulants that are poised to prevent thrombosis without causing serious bleeding. Creative’s high-quality antibodies are essential for the discovery and development of this promising new class of safe and effective antithrombotic therapeutics.

    F11: A Key Target for Safer Anticoagulation

    Coagulation Factor XI (F11) is a serine protease of the intrinsic pathway of blood coagulation. It is cleaved and activated by Factor XIIa and, in turn, cleaves and activates Factor IX. Its role was considered to be redundant for many years. Epidemiological and clinical studies have shown that, unusually, high levels of this Factor are a major risk factor for thrombosis (clotting), and that people who are genetically deficient in F11 are at extremely low risk of thrombosis and, importantly, do not have spontaneous bleeding. This striking “separation of thrombosis from hemostasis” has turned F11 into one of the most exciting targets for development of a new generation of anticoagulants that can prevent clots with none of the major bleeding side effects of current drugs.

    Alternative Names

    FXI; PTA

    Background

    This gene encodes coagulation factor XI of the blood coagulation cascade. This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. During activation of the plasma factor XI, an internal peptide bond is cleaved by factor XIIa (or XII) in each of the two chains, resulting in activated factor XIa, a serine protease composed of two heavy and two light chains held together by disulfide bonds. This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality.

    Protein class

    Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins

    Predicted location

    Intracellular, Secreted (different isoforms)

    Single cell type specificity

    Group enriched (Hepatocytes, Alveolar cells type 2)

    Immune cell specificity

    Not detected in immune cells

    Cell line specificity

    Cell line enriched (Hep G2)

    Interaction

    Homodimer; disulfide-linked. Forms a heterodimer with SERPINA5. After activation the heavy and light chains are also linked by a disulfide bond.

    Molecular function

    Heparin-binding, Hydrolase, Protease, Serine protease

    More Types Infomation

    Anti-F11 rAb Products

    Creative Biolabs’ anti-F11 recombinant antibodies have been engineered for high affinity and potent neutralizing activity. They are extensively validated for detecting F11 in plasma as well as, critically, for blocking its activation and enzymatic activity. Optimized for ELISA, functional assays and as benchmark controls for in vivo thrombosis models, our rAbs are the premier antibodies for drug discovery.

    Table 1. Featured anti-F11 recombinant antibody products at Creative Biolabs.

    Cat. No. Product Name Target Species Host Species Applications
    HPAB-0153-WJ Human Anti-F11 Recombinant Antibody (HPAB-0153-WJ) Human Human IgG1 ELISA
    HPAB-2257LY Mouse Anti-F11 Recombinant Antibody (HPAB-2257LY) Human, Mouse, Rat, Monkey Mouse IgG ELISA
    HPAB-2299LY Humanized Anti-F11 Recombinant Antibody (HPAB-2299LY) Human Humanized IgG ELISA, FC, REA, WB, Inhibition

    Customer Reviews

    Excellent
    Ch**e
    Humanized Anti-F11 Recombinant Antibody (HPAB-2299LY)
    The lot-to-lot consistency of Creative Biolabs’ antibodies is phenomenal. The anti-F11 has provided consistent data over the entire lifetime of our long-term drug development program.
    13/Sep/2024

    rAb Production

    To enable rapid development of next generation therapies, Creative Biolabs uses cutting-edge production platforms. Our anti-F11 recombinant antibodies are engineered, developed and extensively screened to ensure potent, high-affinity neutralization.

    Featured Anti-F11 Recombinant Antibody Production PlatformsFig.1 Milligram-scale. (Creative Biolabs Original)
    Fig.1 Milligram-scale anti-F11 recombinant antibody production.

    Fig.2 Gram-scale. (Creative Biolabs Original)Fig.2 Gram-scale anti-F11 recombinant antibody production.

    rAb Modalities

    Creative Biolabs is committed to delivering advanced solutions for thrombosis research. Creative’s anti-F11 recombinant antibodies are available in a variety of modalities, including potent neutralizing IgGs and Fab fragments, to empower researchers all over the world to study this important antithrombotic target.

    Fig.3 F11 antibody production and modalities. (Creative Biolabs Original)Fig.3 Full-length anti-F11 recombinant antibody production and modalities.

    F11-Targeted Drug Information

    Table 2. Public drug targeting F11.

    Company
    Research Phase
    Classification
    Condition
    Anthos Therapeutics (BMS)
    Phase 3
    Monoclonal Antibody (Inhibitor)
    Thrombosis Prevention (e.g., in Atrial Fibrillation)
    Bayer
    Phase 3
    Monoclonal Antibody (Inhibitor)
    End-Stage Renal Disease, Thrombosis
    Ionis Pharmaceuticals
    Phase 2
    Antisense Oligonucleotide (ASO)
    Thrombosis
    Novo Nordisk
    Approved
    Monoclonal Antibody (targets TFPI)
    (Different mechanism but related field)

    (Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

    Lead the next generation of safer anticoagulants with Creative Biolabs’ potent anti-F11 neutralizing antibodies. Creative’s portfolio provides high-affinity antibodies as well as functional validation to support development of next generation thrombosis therapeutics. Partner with us for quality that advances novel drug discovery. Contact our specialists today.

    Go to compare

    Go to compare